2008
DOI: 10.2174/157489108786242369
|View full text |Cite
|
Sign up to set email alerts
|

Hepatitis C Virus NS3/4A Protease Inhibitors

Abstract: Chronic hepatitis C virus infection is a global problem worldwide due to the lack of an effective therapy (the current standard of care treatment is effective in about 40-50% of the cases), and the difficulties in developing a protective vaccine. Chronic infection progresses to end-stage liver disease and liver failure in a considerable number of infected individuals. Once liver function is compromised, the only reliable therapeutic intervention is liver transplantation. Unfortunately, re-infection of the graf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
17
0

Year Published

2010
2010
2014
2014

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(18 citation statements)
references
References 0 publications
1
17
0
Order By: Relevance
“…Herein we describe an integrated strategy for identifying fragment inhibitors using computational techniques. Due to increase in HCV infection cases and lack of effective therapies, there is a need to develop specific compounds that can target the HCV [12]. Therefore, this study was planned to molecularly characterize the Pakistani HCV helicase protein.…”
Section: Introductionmentioning
confidence: 99%
“…Herein we describe an integrated strategy for identifying fragment inhibitors using computational techniques. Due to increase in HCV infection cases and lack of effective therapies, there is a need to develop specific compounds that can target the HCV [12]. Therefore, this study was planned to molecularly characterize the Pakistani HCV helicase protein.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, the HCV NS3 protein is at present considered to not only be an attractive constituent for the production of an anti-HCV vaccine (Zeng et al 2009), but also an important target for the development of new therapeutic protease inhibitors (Enomoto et al 2009). To date, several specific NS3-4A S protease inhibitors, such as VX-950, SCH6, SCH503034, ITMN-191 and TMC435350, have been designed and are currently being evaluated in clinical trials (López-Labrador 2008). However, given the high level of variability of HCV, which is a result of the error-prone nature of RNA-dependent RNA polymerase, variants resistant to a number of protease inhibitors have been identified (Peres-da-Silva et al 2010, Vermehren & Sarrazin 2011) and represent a current challenge for therapy with DAAs.…”
mentioning
confidence: 99%
“…After the success of protease inhibitors in the treatment of human-immunodeficiency virus-1 (HIV) infection, it is thought that development of a specific inhibitors of NS3 protease activity would be an attractive target for new anti-HCV drugs [10,16]. The inhibition of NS3/4A protease will interfere with the viral life cycle and restore the pathways of innate immunity [17].…”
Section: Ns3 Inhibitorsmentioning
confidence: 99%
“…This combination treatment can be used to decline HCV infection cases and people who do not respond to monotherapy. Due to increase in HCV infection cases and lack of effective therapies, there is a need to develop specific compounds that can target important factors of the HCV life cycle [10].…”
Section: Introductionmentioning
confidence: 99%